GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0006979111 | Esophagus | ESCC | response to oxidative stress | 303/8552 | 446/18723 | 7.15e-22 | 1.30e-19 | 303 |
GO:0062197111 | Esophagus | ESCC | cellular response to chemical stress | 234/8552 | 337/18723 | 5.37e-19 | 5.97e-17 | 234 |
GO:0034599111 | Esophagus | ESCC | cellular response to oxidative stress | 197/8552 | 288/18723 | 3.76e-15 | 2.15e-13 | 197 |
GO:00063833 | Esophagus | ESCC | transcription by RNA polymerase III | 41/8552 | 46/18723 | 7.69e-10 | 1.90e-08 | 41 |
GO:000635211 | Esophagus | ESCC | DNA-templated transcription, initiation | 86/8552 | 130/18723 | 1.88e-06 | 2.19e-05 | 86 |
GO:00708973 | Esophagus | ESCC | transcription preinitiation complex assembly | 30/8552 | 36/18723 | 3.60e-06 | 3.95e-05 | 30 |
GO:0006359 | Esophagus | ESCC | regulation of transcription by RNA polymerase III | 19/8552 | 22/18723 | 9.52e-05 | 6.78e-04 | 19 |
GO:000697920 | Oral cavity | OSCC | response to oxidative stress | 273/7305 | 446/18723 | 8.35e-22 | 1.65e-19 | 273 |
GO:006219720 | Oral cavity | OSCC | cellular response to chemical stress | 204/7305 | 337/18723 | 6.89e-16 | 5.19e-14 | 204 |
GO:003459920 | Oral cavity | OSCC | cellular response to oxidative stress | 173/7305 | 288/18723 | 2.90e-13 | 1.43e-11 | 173 |
GO:00063832 | Oral cavity | OSCC | transcription by RNA polymerase III | 34/7305 | 46/18723 | 1.61e-06 | 2.11e-05 | 34 |
GO:00063522 | Oral cavity | OSCC | DNA-templated transcription, initiation | 74/7305 | 130/18723 | 2.56e-05 | 2.39e-04 | 74 |
GO:00708972 | Oral cavity | OSCC | transcription preinitiation complex assembly | 24/7305 | 36/18723 | 7.18e-04 | 3.95e-03 | 24 |
GO:0006979110 | Oral cavity | LP | response to oxidative stress | 181/4623 | 446/18723 | 5.74e-14 | 6.10e-12 | 181 |
GO:0062197110 | Oral cavity | LP | cellular response to chemical stress | 130/4623 | 337/18723 | 8.94e-09 | 3.52e-07 | 130 |
GO:0034599110 | Oral cavity | LP | cellular response to oxidative stress | 110/4623 | 288/18723 | 2.19e-07 | 6.65e-06 | 110 |
GO:007089711 | Oral cavity | LP | transcription preinitiation complex assembly | 17/4623 | 36/18723 | 2.74e-03 | 1.92e-02 | 17 |
GO:00063831 | Oral cavity | LP | transcription by RNA polymerase III | 20/4623 | 46/18723 | 4.03e-03 | 2.61e-02 | 20 |
GO:00063521 | Oral cavity | LP | DNA-templated transcription, initiation | 45/4623 | 130/18723 | 7.03e-03 | 3.96e-02 | 45 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
BRF2 | SNV | Missense_Mutation | novel | c.746G>A | p.Arg249Gln | p.R249Q | Q9HAW0 | protein_coding | tolerated(0.14) | benign(0) | TCGA-A7-A5ZX-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | CR |
BRF2 | SNV | Missense_Mutation | | c.877G>T | p.Val293Leu | p.V293L | Q9HAW0 | protein_coding | deleterious(0) | possibly_damaging(0.625) | TCGA-A8-A09I-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
BRF2 | insertion | Frame_Shift_Ins | novel | c.158_159insC | p.Thr54AsnfsTer13 | p.T54Nfs*13 | Q9HAW0 | protein_coding | | | TCGA-A7-A0CJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
BRF2 | insertion | Frame_Shift_Ins | novel | c.157_158insGAGGCGGAGCTTGCAGTGAGCCGAGA | p.Val53GlyfsTer10 | p.V53Gfs*10 | Q9HAW0 | protein_coding | | | TCGA-A7-A0CJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
BRF2 | insertion | In_Frame_Ins | novel | c.707_708insTTCTAATATGTCTGT | p.Ser236_Leu237insSerAsnMetSerVal | p.S236_L237insSNMSV | Q9HAW0 | protein_coding | | | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
BRF2 | insertion | Frame_Shift_Ins | novel | c.259_260insATGTAAAAGGATGTGGG | p.Pro87HisfsTer43 | p.P87Hfs*43 | Q9HAW0 | protein_coding | | | TCGA-BH-A0AW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
BRF2 | insertion | Frame_Shift_Ins | novel | c.258_259insTCTCTTTTTTACCAAAGCC | p.Pro87SerfsTer10 | p.P87Sfs*10 | Q9HAW0 | protein_coding | | | TCGA-BH-A0AW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
BRF2 | SNV | Missense_Mutation | | c.247N>A | p.Leu83Met | p.L83M | Q9HAW0 | protein_coding | deleterious(0) | possibly_damaging(0.729) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
BRF2 | SNV | Missense_Mutation | | c.994G>A | p.Gly332Arg | p.G332R | Q9HAW0 | protein_coding | tolerated(0.47) | benign(0.003) | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD |
BRF2 | SNV | Missense_Mutation | rs140725525 | c.497C>T | p.Ser166Phe | p.S166F | Q9HAW0 | protein_coding | tolerated(0.06) | possibly_damaging(0.553) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |